ORIGINAL ARTICLE

original article

Diabetes, Obesity and Metabolism 18: 1072–1080, 2016. © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4 T. Blevins1 , T. R. Pieber2 , G. Colón Vega3 , S. Zhang4 , E. J. Bastyr III4,5 , A. M. Chang4 on behalf of the IMAGINE 4 Investigators 1 Texas Diabetes and Endocrinology, Austin, TX, USA 2 Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria 3 American Telemedicine Center, San Juan, Puerto Rico 4 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA 5 Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA

Aims: To evaluate the efficacy and safety of basal insulin peglispro (BIL) with those of insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (T2D). Methods: In this phase III, multicentre, double-blind, 26-week study, we randomized patients with T2D [glycated haemoglobin (HbA1c) ≥7 and

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.

To evaluate the efficacy and safety of basal insulin peglispro (BIL) with those of insulin glargine, both in combination with prandial insulin lispro,...
374KB Sizes 0 Downloads 10 Views

Recommend Documents